. Author manuscript; available in PMC: 2019 Jul 17.

Published in final edited form as: Obstet Gynecol. 2017 Feb;129(2):355–362. doi: 10.1097/AOG.0000000000001838

Table 3.

Enhanced Recovery Protocols in Gynecologic Oncology Surgery in Which Primary Outcome Included Length of Hospital Stay

	Study
Design Variable	Marx et al¹¹	Chase et al¹²	Gerardi et al¹³	Carter¹⁴	Kalogera et al¹⁵	Wijk et al¹⁶	Present Study

Prospective Design	No Sequential cohorts	No Cohort	No Case–control	No Cohort	No Sequential cohorts	Yes Sequential cohorts	Yes RCT
Sample size
Control	72	NA	45	NA	158^*	120	52
ERAS	69	880	19	389	165^†	85	51
% with gynecologic malignancy
Control	100	NR	100	NR	100	28	71
ERAS	100	48	100	58	100	38	57
% with bowel surgery
Control	13	NR	100	NR	24	NR	9.6
ERAS	7	NR	100	NR	22	NR	11.8
Length of stay (median)
Control	6		10		4 staging; 8 cytoreduction	2	3
ERAS	5	2	7	3	4 staging; 5 cytoreduction	2	3
% readmitted
Control	9.7		33		15	4.2	5.8
ERAS	2.9	5	21	4	20	3.5	7.8
Protocol directed length of stay (target)	ERAS only (POD 4)	Yes (POD 2)	No	No	NR	Yes (POD 2)	No

Seventy-seven vaginal cases excluded.

^†

Seventy-six vaginal cases excluded.

RCT, randomized controlled trial; NA, not applicable; ERAS, enhanced recovery after surgery; NR, not reported; POD, postoperative day.